Otros idiomas Bausch Health Companies Inc.

Acciones

BHC

CA0717341071

Mercado cerrado - Nyse Otros sitios de cotización 22:00:01 14/06/2024			Varia. Cinco días.	Varia. 1 de enero.
6,32 ^USD	+2,43 %		+0,80 %	-21,20 %

23/05	Bausch Health anuncia una mayor cobertura del plan público de medicamentos para Uceris en Canadá	MT
17/05	Bausch Health Companies Inc. y Salix Pharmaceuticals presentarán datos de última hora del ensayo de fase 2 de amiselimod en colitis ulcerosa activa en la Semana de las Enfermedades Digestivas 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	03/06
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	28/05
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	23/05
Bausch Health Companies - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	20/05
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	17/05
Bausch Health Announces 2024 Annual Meeting of Shareholder Results	16/05
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	15/05
Bausch Health Companies Inc. Approves Directorate Appointments	15/05
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	14/05
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	14/05
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	13/05
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	03/05
Bausch Health Announces First Quarter 2024 Results	03/05
Bausch Health Shares Fall Following Q1 Results	02/05
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	02/05
Bausch: Q1 Earnings Snapshot	02/05
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	02/05
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	02/05
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	02/05
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Bausch Health Companies Inc.

Acciones

BHC

CA0717341071

Otros idiomas

Filtros